Brokerages predict that Fluidigm Co. (NASDAQ:FLDM) will announce ($0.08) earnings per share for the current quarter, according to Zacks. Three analysts have issued estimates for Fluidigm’s earnings, with estimates ranging from ($0.11) to ($0.05). Fluidigm reported earnings of ($0.42) per share during the same quarter last year, which would indicate a positive year over year growth rate of 81%. The company is expected to issue its next earnings results after the market closes on Thursday, August 1st.
According to Zacks, analysts expect that Fluidigm will report full year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.41) to ($0.30). For the next year, analysts expect that the firm will post earnings of ($0.18) per share, with EPS estimates ranging from ($0.25) to ($0.11). Zacks’ EPS calculations are an average based on a survey of analysts that cover Fluidigm.
Fluidigm (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.30). Fluidigm had a negative return on equity of 43.75% and a negative net margin of 60.45%. The firm had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $29.18 million. The business’s revenue was up 19.4% on a year-over-year basis.
In other news, insider Levin Easterly Partners Llc sold 186,759 shares of Fluidigm stock in a transaction on Monday, July 1st. The stock was sold at an average price of $12.31, for a total value of $2,299,003.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nicolas Barthelemy sold 5,100 shares of Fluidigm stock in a transaction on Monday, June 17th. The shares were sold at an average price of $12.43, for a total value of $63,393.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 566,356 shares of company stock valued at $6,964,366. Insiders own 2.00% of the company’s stock.
Several large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its position in shares of Fluidigm by 3,543.1% in the first quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock worth $91,000 after buying an additional 6,661 shares during the period. United Services Automobile Association purchased a new stake in shares of Fluidigm in the fourth quarter worth about $102,000. Brown Advisory Inc. purchased a new stake in shares of Fluidigm in the fourth quarter worth about $115,000. Bank of America Corp DE boosted its position in shares of Fluidigm by 149.3% in the fourth quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after buying an additional 8,654 shares during the period. Finally, SMH Capital Advisors Inc. purchased a new stake in shares of Fluidigm in the first quarter worth about $146,000. 92.64% of the stock is owned by institutional investors and hedge funds.
Shares of FLDM stock traded down $0.09 during midday trading on Thursday, hitting $10.90. The company had a trading volume of 52,578 shares, compared to its average volume of 1,015,089. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.86 and a current ratio of 3.26. Fluidigm has a 52-week low of $5.50 and a 52-week high of $14.90. The firm has a market capitalization of $758.53 million, a PE ratio of -13.63 and a beta of 2.16. The stock has a 50 day simple moving average of $12.22.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Story: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.